ArticleActa neurochirurgica2026
Survival and prognostic factors of anaplastic hemangiopericytoma/solitary fibrous tumor grade III.
Article in Acta neurochirurgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnaplastic Hemangiopericytoma (AHPC), now known as Solitary Fibrous Tumor (SFT) Grade III, is a rare biologically aggressive neoplasm with a high rate of recurrence. Owing to its rarity, the existing literature is limited regarding its clinical characteristics, prognostic factors, management, and treatment strategies. In this study, we evaluate the association between patient demographics, clinical variables, and treatment modalities with overall survival in patients with intracranial AHPC/SFT Grade III.
methodsThe National Cancer Database (NCDB) was queried for the clinical and care parameters of patients ≥ 18-years-old diagnosed with AHPC between 2004 and 2017. Multivariable Cox proportional hazards model was implemented to determine factors associated with overall survival.
results427 patients were identified with a mean age of 52.6 ± 0.7 years. Most patients were between 40-70 years old (67.0%) with patients ≤ 40-years-old making up 21.3% and those ≥ 70-years-old making up only 11.7%. Overall median survival was 10.8 years. When stratified based on age, those ≤ 40-years-old had increased mean survival compared to those ≥ 70-years-old (10.8 vs. 6.6 years; p < 0.001). On multivariable analysis, increasing age (p = 0.006) and the receipt of chemotherapy was associated with decreased overall survival. In contrast, private insurance and managed care (p = 0.021), treatment with surgery alone (p = 0.003), or combined surgery and radiation therapy (p = 0.001) were independently associated with significantly improved overall survival.
conclusionIn this NCDB cohort of intracranial grade III SFT/HPC, improved overall survival was associated with younger age, private insurance status, and treatment with surgery alone or surgery combined with radiation therapy. Chemotherapy was not associated with a survival benefit. Interpretation of treatment effects should be cautious, given the potential for selection bias in chemotherapy utilization and the risk of immortal time bias analyses of radiotherapy. Continued advances in therapeutic strategies are needed to further improve survival in this rare and clinically devastating disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.